To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients
Status: | Completed |
---|---|
Conditions: | Migraine Headaches |
Therapuetic Areas: | Neurology |
Healthy: | No |
Age Range: | 18 - 45 |
Updated: | 12/29/2017 |
Start Date: | November 11, 2015 |
End Date: | November 8, 2017 |
Phase I, Randomized, Parallel-group, Double-Blind, Placebo-Controlled, Single Dose Study to Evaluate the Blockade of CGRP Receptor by AMG 334 in Preventing PACAP-38 Induced Migraine-like Attacks in Migraine Patients
Phase I, Randomized, Parallel-group, Double-Blind, Placebo-Controlled, Single Dose Study to
Evaluate the Blockade of CGRP Receptor by AMG 334 in Preventing PACAP-38 Induced
Migraine-like Attacks in Migraine Patients.
Evaluate the Blockade of CGRP Receptor by AMG 334 in Preventing PACAP-38 Induced
Migraine-like Attacks in Migraine Patients.
Inclusion Criteria:
- Adults ≥ 18 to ≤ 45 years of age upon entry into screening
- History of migraine headaches without aura for ≥ 6 months prior to screening according
to the IHS Classification ICHD-II (Headache Classification Committee of the
International Headache Society, 2004) based on medical records and/or patient
self-report
- Migraine frequency: ≥ 1 and ≤ 5 migraine days per month in each of the 3 months prior
to screening
Exclusion Criteria:
- History of migraine with aura, cluster headache or hemiplegic migraine headache
according to the IHS Classification ICHD-II (Headache Classification Committee of the
International Headache Society, 2004) based on medical records and/or patient
self-report
- ≥ 6 migraine days per month in the last 3 months prior to study enrollment and during
screening period
- Other headache disorders (except for episodic tension-type headache <5 days/month)
We found this trial at
2
sites
Click here to add this to my saved trials
Click here to add this to my saved trials